These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase. Humnabadkar V; Madhavapeddi P; Basavarajappa H; Sheikh MG; Rane R; Basu R; Verma P; Sundaram A; Mukherjee K; de Sousa SM J Biomol Screen; 2015 Feb; 20(2):265-74. PubMed ID: 25300873 [TBL] [Abstract][Full Text] [Related]
3. A High Throughput Screening Assay for Anti-Mycobacterial Small Molecules Based on Adenylate Kinase Release as a Reporter of Cell Lysis. Forbes L; Ebsworth-Mojica K; DiDone L; Li SG; Freundlich JS; Connell N; Dunman PM; Krysan DJ PLoS One; 2015; 10(6):e0129234. PubMed ID: 26098625 [TBL] [Abstract][Full Text] [Related]
5. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Taneja NK; Tyagi JS J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560 [TBL] [Abstract][Full Text] [Related]
6. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Goldman RC Tuberculosis (Edinb); 2013 Nov; 93(6):569-88. PubMed ID: 24119636 [TBL] [Abstract][Full Text] [Related]
7. Anti-TB drug resistance levels and patterns among Mycobacterium tuberculosis isolated from newly diagnosed cases of pulmonary tuberculosis in Dar es Salaam, Tanzania. Matee M; Mfinanga S; Holm-Hansen C APMIS; 2009 Apr; 117(4):263-7. PubMed ID: 19338514 [TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
9. Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense. Kaur P; Datta S; Shandil RK; Kumar N; Robert N; Sokhi UK; Guptha S; Narayanan S; Anbarasu A; Ramaiah S PLoS One; 2016; 11(5):e0154513. PubMed ID: 27144597 [TBL] [Abstract][Full Text] [Related]
10. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054 [TBL] [Abstract][Full Text] [Related]
11. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134 [TBL] [Abstract][Full Text] [Related]
12. The Deconstructed Granuloma: A Complex High-Throughput Drug Screening Platform for the Discovery of Host-Directed Therapeutics Against Tuberculosis. Huang L; Kushner NL; Theriault ME; Pisu D; Tan S; McNamara CW; Petrassi HM; Russell DG; Brown AC Front Cell Infect Microbiol; 2018; 8():275. PubMed ID: 30155446 [No Abstract] [Full Text] [Related]
13. An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis. Gupta A; Bhakta S J Antimicrob Chemother; 2012 Jun; 67(6):1380-91. PubMed ID: 22398649 [TBL] [Abstract][Full Text] [Related]
14. Differences in drug resistance profiles of Mycobacterium tuberculosis isolates causing pulmonary and extrapulmonary tuberculosis in a medical centre in Taiwan, 2000-2010. Lai CC; Liu WL; Tan CK; Huang YC; Chung KP; Lee MR; Hsueh PR Int J Antimicrob Agents; 2011 Aug; 38(2):125-9. PubMed ID: 21592735 [TBL] [Abstract][Full Text] [Related]
15. Plants from Puerto Rico with anti-Mycobacterium tuberculosis properties. Frame AD; Ríos-Olivares E; De Jesús L; Ortiz D; Pagán J; Méndez S P R Health Sci J; 1998 Sep; 17(3):243-52. PubMed ID: 9883470 [TBL] [Abstract][Full Text] [Related]
16. Determination of ethambutol MICs for Mycobacterium tuberculosis and Mycobacterium avium isolates by resazurin microtitre assay. Jadaun GP; Agarwal C; Sharma H; Ahmed Z; Upadhyay P; Faujdar J; Gupta AK; Das R; Gupta P; Chauhan DS; Sharma VD; Katoch VM J Antimicrob Chemother; 2007 Jul; 60(1):152-5. PubMed ID: 17483147 [TBL] [Abstract][Full Text] [Related]
17. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model. Sarkar S; Sarkar D J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731 [TBL] [Abstract][Full Text] [Related]
18. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]